ResMed Inc. RMD
Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Ask Irving AI About RMD
Get to know the stock you’re researching through a simple conversation. Ask Irving about its Weiss rating, financial health, dividends, and potential risks — right from the stock page.
Get answers about this stock. Instantly.
Ask about the company’s financial health and its Weiss Safety, Reward, and Risk Ratings, with answers grounded in Weiss Ratings data.
Understand the numbers behind the rating.
Explore profits, cash flow, valuation, and dividends. Ask follow-up questions without leaving the stock page.
Put the stock’s strengths and risks in context.
Look beyond a single number. Explore rating changes and company trends to better understand the stock’s outlook.
Company Overview
ResMed Inc. is a medical technology company focused on sleep health, respiratory care, and out-of-hospital healthcare software solutions. The company develops and manufactures cloud-connected medical devices and digital health platforms primarily used to diagnose, treat, and manage sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory disorders. ResMed operates within the global healthcare equipment, medical devices, and healthcare software industries, with recurring revenue generated through device sales, masks and consumables, and software-as-a-service offerings. Its primary customer base includes sleep clinics, hospitals, home healthcare providers, durable medical equipment distributors, physicians, and patients receiving home-based care.
ResMed was founded in 1989 by Peter Farrell following research related to sleep-disordered breathing technologies developed by Dr. Colin Sullivan. The company expanded from its original continuous positive airway pressure (CPAP) device business into a broader digital health and connected-care platform provider through acquisitions and software investments. ResMed is widely recognized for its connected device ecosystem, large installed base in sleep apnea therapy, and integrated cloud-based patient monitoring infrastructure, which supports remote patient management and compliance tracking across healthcare networks.
Business Operations
ResMed generates revenue primarily through its Sleep and Respiratory Care segment and its Software as a Service (SaaS) operations. The company’s medical device portfolio includes CPAP and bilevel devices, ventilators, masks, diagnostic tools, and associated accessories used in home and clinical settings. Recurring mask and consumable sales represent an important revenue contributor due to ongoing patient replacement cycles. Its software operations include healthcare management platforms designed for out-of-hospital providers, including nursing facilities, home health agencies, and hospice organizations. Key software businesses include Brightree, MatrixCare, and MEDIFOX DAN, which support workflow automation, billing, analytics, and patient care coordination.
The company operates across both domestic and international markets, with substantial operations in North America, Europe, and Asia-Pacific. ResMed maintains manufacturing, research, and distribution capabilities across multiple countries and leverages cloud-based technologies through its proprietary digital health ecosystem, including the AirView remote monitoring platform. Strategic partnerships with healthcare providers, payers, and distributors support market penetration and patient adoption. The company also maintains a portfolio of subsidiaries supporting healthcare software, respiratory care distribution, and digital patient engagement services.
Strategic Position & Investments
ResMed’s strategic direction centers on expanding connected healthcare capabilities, increasing adoption of sleep apnea diagnosis and therapy, and strengthening its digital health software ecosystem. The company has consistently invested in cloud-connected medical devices, artificial intelligence-enabled patient management tools, and data-driven healthcare platforms designed to improve adherence and operational efficiency. Growth initiatives have focused on increasing global CPAP penetration, scaling recurring mask sales, and expanding software offerings serving post-acute and home-based healthcare providers.
Major acquisitions have played a significant role in ResMed’s expansion strategy. Notable transactions include the acquisitions of Brightree, MatrixCare, and MEDIFOX DAN, which expanded the company’s presence in healthcare SaaS and post-acute care software markets. ResMed has also invested in digital diagnostics, remote patient monitoring technologies, and integrated care management solutions. The company continues to position itself at the intersection of medical devices and digital health, emphasizing long-term growth in home healthcare and decentralized care delivery.
Geographic Footprint
ResMed is headquartered in San Diego, California, and maintains a significant global operating presence across more than 140 countries. The company has major commercial operations throughout North America, Europe, and Asia-Pacific, with additional reach in Latin America, the Middle East, and Africa. Manufacturing, research, and distribution facilities are located across the United States, Singapore, Australia, France, and other international markets.
International revenue represents a substantial portion of ResMed’s overall business, supported by localized sales organizations and distribution networks. The company has historically maintained strong market positions in United States, Australia, Germany, France, United Kingdom, and several Asian healthcare markets. Its software businesses also provide operational infrastructure to healthcare providers across multiple regions, strengthening the company’s international influence in out-of-hospital care delivery and digital healthcare administration.
Leadership & Governance
ResMed’s leadership team combines medical technology, digital health, and software industry expertise. Founder Peter Farrell played a central role in establishing the company’s early market position in sleep-disordered breathing therapy. Current leadership has continued to prioritize connected healthcare technologies, operational scale, and data-driven patient care solutions. The company emphasizes innovation, clinical outcomes improvement, and expansion of home-based healthcare services as core strategic principles.
Key executives include:
- Michael J. Farrell – Chairman and Chief Executive Officer
- Brett Sandercock – Chief Financial Officer
- Mick Farrell – Chief Executive Officer and Chairman
- Rob Douglas – President and Chief Operating Officer
- Carlos M. Nunez, M.D. – Chief Medical Officer
- Justin Leong – Chief Product Officer
- Katrina Cole – Chief Human Resources Officer
ResMed’s governance structure includes an independent board of directors and public reporting obligations through filings with the U.S. Securities and Exchange Commission (SEC). Public disclosures, annual reports, earnings materials, and investor presentations consistently identify digital health expansion, patient-centric innovation, and global operational growth as core elements of management strategy.